| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| azd5363 | rac-alpha serine/threonine-protein kinase | NA | Clinical trial target | TTD , DGIDB | Triple Negative Breast Neoplasms[MeSHID:D064726] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
1.07 | phase 3 | inhibitor |
| azd5363 | rac-alpha serine/threonine-protein kinase | NA | Clinical trial target | TTD , DGIDB | Triple Negative Breast Neoplasms[MeSHID:D064726] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
1.07 | phase 3 | unknown |
| azd5363 | rac-gamma serine/threonine-protein kinase | NA | Clinical trial target | TTD , DGIDB | Triple Negative Breast Neoplasms[MeSHID:D064726] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
0.92 | phase 3 | unknown |
| click here to return to the previous page | ||||||||